Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912781839> ?p ?o ?g. }
- W2912781839 endingPage "440" @default.
- W2912781839 startingPage "440" @default.
- W2912781839 abstract "Levetiracetam is a commonly used antiepileptic drug, yet psychiatric adverse effects are common and may lead to treatment discontinuation.To derive prediction models to estimate the risk of psychiatric adverse effects from levetiracetam use.Retrospective open cohort study. All patients meeting the case definition for epilepsy after the Acceptable Mortality Reporting date in The Health Improvement Network (THIN) database based in the United Kingdom (inclusive January 1, 2000, to May 31, 2012) who received a first-ever prescription for levetiracetam were included. Of 11 194 182 patients registered in THIN, this study identified 7400 presumed incident cases (66.1 cases per 100 000 persons) over a maximum of 12 years' follow-up. The index date was when patients received their first prescription code for levetiracetam, and follow-up lasted 2 years or until an event, loss to follow-up, or censoring. The analyses were performed on April 22, 2018.A presumed first-ever prescription for levetiracetam.The outcome of interest was a Read code for any psychiatric sign, symptom, or disorder as reached through consensus by 2 authors. This study used regression techniques to derive 2 prediction models, one for the overall population and one for those without a history of a psychiatric sign, symptom, or disorder during the study period.Among 1173 patients with epilepsy receiving levetiracetam, the overall median age was 39 (interquartile range, 25-56) years, and 590 (50.3%) were female. A total of 14.1% (165 of 1173) experienced a psychiatric symptom or disorder within 2 years of index prescription. The odds of reporting a psychiatric symptom were significantly elevated for women (odds ratio [OR], 1.41; 95% CI, 0.99-2.01; P = .05) and those with a preexposure history of higher social deprivation (OR, 1.15; 95% CI, 1.01-1.31; P = .03), depression (OR, 2.20; 95% CI, 1.49-3.24; P < .001), anxiety (OR, 1.74; 95% CI, 1.11-2.72; P = .02), or recreational drug use (OR, 2.02; 95% CI, 1.20-3.37; P = .008). The model performed well after stratified k = 5-fold cross-validation (area under the curve [AUC], 0.68; 95% CI, 0.58-0.79). There was a gradient in risk, with probabilities increasing from 8% for 0 risk factors to 11% to 17% for 1, 17% to 31% for 2, 30% to 42% for 3, and 49% when all risk factors were present. For those free of a preexposure psychiatric code, a second model performed comparably well after k = 5-fold cross-validation (AUC, 0.72; 95% CI, 0.54-0.90). Specificity was maximized using threshold cutoffs of 0.10 (full model) and 0.14 (second model); a score below these thresholds indicates safety of prescription.This study derived 2 simple models that predict the risk of a psychiatric adverse effect from levetiracetam. These algorithms can be used to guide prescription in clinical practice." @default.
- W2912781839 created "2019-02-21" @default.
- W2912781839 creator A5001067063 @default.
- W2912781839 creator A5002247666 @default.
- W2912781839 creator A5007528691 @default.
- W2912781839 creator A5012744052 @default.
- W2912781839 creator A5025225575 @default.
- W2912781839 creator A5026830121 @default.
- W2912781839 creator A5044349713 @default.
- W2912781839 creator A5049401142 @default.
- W2912781839 creator A5055296816 @default.
- W2912781839 creator A5061256516 @default.
- W2912781839 creator A5067232569 @default.
- W2912781839 creator A5068320077 @default.
- W2912781839 creator A5076076754 @default.
- W2912781839 creator A5080971882 @default.
- W2912781839 creator A5088005270 @default.
- W2912781839 date "2019-04-01" @default.
- W2912781839 modified "2023-10-17" @default.
- W2912781839 title "Prediction Tools for Psychiatric Adverse Effects After Levetiracetam Prescription" @default.
- W2912781839 cites W1691887444 @default.
- W2912781839 cites W1976451939 @default.
- W2912781839 cites W1981565893 @default.
- W2912781839 cites W2001310603 @default.
- W2912781839 cites W2006000121 @default.
- W2912781839 cites W2006817220 @default.
- W2912781839 cites W2016405071 @default.
- W2912781839 cites W2022425171 @default.
- W2912781839 cites W2024794524 @default.
- W2912781839 cites W2030895227 @default.
- W2912781839 cites W2033945449 @default.
- W2912781839 cites W2040009475 @default.
- W2912781839 cites W2054268862 @default.
- W2912781839 cites W2061839656 @default.
- W2912781839 cites W2077008944 @default.
- W2912781839 cites W2081167060 @default.
- W2912781839 cites W2084780586 @default.
- W2912781839 cites W2097529890 @default.
- W2912781839 cites W2105566111 @default.
- W2912781839 cites W2119193334 @default.
- W2912781839 cites W2119910794 @default.
- W2912781839 cites W2129285949 @default.
- W2912781839 cites W2135373623 @default.
- W2912781839 cites W2158985195 @default.
- W2912781839 cites W2160193088 @default.
- W2912781839 cites W2169101721 @default.
- W2912781839 cites W2180981774 @default.
- W2912781839 cites W2318658284 @default.
- W2912781839 cites W2510367931 @default.
- W2912781839 cites W2563036039 @default.
- W2912781839 cites W2610533508 @default.
- W2912781839 cites W2757684821 @default.
- W2912781839 cites W2763503006 @default.
- W2912781839 cites W2775393523 @default.
- W2912781839 cites W2799492142 @default.
- W2912781839 cites W4234714993 @default.
- W2912781839 cites W4249999102 @default.
- W2912781839 doi "https://doi.org/10.1001/jamaneurol.2018.4561" @default.
- W2912781839 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6459128" @default.
- W2912781839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30688969" @default.
- W2912781839 hasPublicationYear "2019" @default.
- W2912781839 type Work @default.
- W2912781839 sameAs 2912781839 @default.
- W2912781839 citedByCount "68" @default.
- W2912781839 countsByYear W29127818392019 @default.
- W2912781839 countsByYear W29127818392020 @default.
- W2912781839 countsByYear W29127818392021 @default.
- W2912781839 countsByYear W29127818392022 @default.
- W2912781839 countsByYear W29127818392023 @default.
- W2912781839 crossrefType "journal-article" @default.
- W2912781839 hasAuthorship W2912781839A5001067063 @default.
- W2912781839 hasAuthorship W2912781839A5002247666 @default.
- W2912781839 hasAuthorship W2912781839A5007528691 @default.
- W2912781839 hasAuthorship W2912781839A5012744052 @default.
- W2912781839 hasAuthorship W2912781839A5025225575 @default.
- W2912781839 hasAuthorship W2912781839A5026830121 @default.
- W2912781839 hasAuthorship W2912781839A5044349713 @default.
- W2912781839 hasAuthorship W2912781839A5049401142 @default.
- W2912781839 hasAuthorship W2912781839A5055296816 @default.
- W2912781839 hasAuthorship W2912781839A5061256516 @default.
- W2912781839 hasAuthorship W2912781839A5067232569 @default.
- W2912781839 hasAuthorship W2912781839A5068320077 @default.
- W2912781839 hasAuthorship W2912781839A5076076754 @default.
- W2912781839 hasAuthorship W2912781839A5080971882 @default.
- W2912781839 hasAuthorship W2912781839A5088005270 @default.
- W2912781839 hasBestOaLocation W29127818391 @default.
- W2912781839 hasConcept C118552586 @default.
- W2912781839 hasConcept C119060515 @default.
- W2912781839 hasConcept C126322002 @default.
- W2912781839 hasConcept C167135981 @default.
- W2912781839 hasConcept C187212893 @default.
- W2912781839 hasConcept C197934379 @default.
- W2912781839 hasConcept C2426938 @default.
- W2912781839 hasConcept C2777332695 @default.
- W2912781839 hasConcept C2778186239 @default.
- W2912781839 hasConcept C2778715236 @default.
- W2912781839 hasConcept C2908647359 @default.
- W2912781839 hasConcept C71924100 @default.